Embracing change: A pharmaceutical industry guide to the 21st century

Translational Medicine and Drug Discovery

Volumn , Issue , 2011, Pages 328-344

  Turner, Mervyn ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927038875     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511976087.015     Document Type: Chapter

References (6)

1. Gilbert C, & Sarkar RG. (2005) Merck: Conflict and change. Harvard Business Review, May 2005.
2. Global pipelines quantified (2007). Merrill Lynch Research Report. August 23, 2007.
3. DiMasi JA, Hansen RW, & Grabowski HG. (2003). The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151–185.
4. Hughes S. (2008). FDA advisory committee recommends cardiovascular safety studies for diabetes drugs. The Heart.org, July 3, 2008.
5. Parexel International. (2007). Pharmaceutical R&D Statistical Source Book 2007/2008, edited byMathieu MP.Waltham, MA: Parexel International. 6. CMR International, 2001–2005 (Major Company Median Comparison). June 2006.
6. FDA. (2008). European Medicines Agency to consider additional test results when assessing new drug safety. FDA News, June 12, 2008.